Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years

Introduction: The effects of tafamidis on mortality in Val30Met and non-Val30Met patients with transthyretin amyloidosis with polyneuropathy (ATTR-PN) were evaluated. Methods: The analyses were based on cumulative data from the Val30Met patients in the 18-month double-blind registration study and it...

Full description

Bibliographic Details
Main Author: Merlini, Giampaolo (author)
Other Authors: Coelho, Teresa (author), Waddington Cruz, Márcia (author), Li, Huihua (author), Stewart, Michelle (author), Ebede, Ben (author)
Format: article
Language:eng
Published: 2022
Subjects:
Amyloidosis; Mortality
Polyneuropathy
Tafamidis
Transthyretin
Val30Met
Online Access:http://hdl.handle.net/10400.16/2685
Country:Portugal
Oai:oai:repositorio.chporto.pt:10400.16/2685

Internet

http://hdl.handle.net/10400.16/2685

Similar Items